Mirum Pharmaceuticals (MIRM) – Investment Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Mirum Pharmaceuticals (NASDAQ: MIRM):

• 9/26/2025 – Mirum Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 9/25/2025 – Mirum Pharmaceuticals was upgraded by analysts at TD Cowen to a “strong-buy” rating.
• 9/24/2025 – Mirum Pharmaceuticals is now covered by analysts at Cowen Inc. They set a “buy” rating on the stock.
• 9/24/2025 – Mirum Pharmaceuticals is now covered by analysts at TD Cowen. They set a “buy” rating and a $95.00 price target on the stock.
• 9/12/2025 – Mirum Pharmaceuticals had its price target raised by analysts at JPMorgan Chase & Co. from $53.00 to $77.00. They now have an “overweight” rating on the stock.
• 8/25/2025 – Mirum Pharmaceuticals was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 8/17/2025 – Mirum Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 8/11/2025 – Mirum Pharmaceuticals was given a new $89.00 price target on by analysts at Stifel Nicolaus. They now have a “buy” rating on the stock.
• 8/9/2025 – Mirum Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 8/8/2025 – Mirum Pharmaceuticals had its price target raised by analysts at Evercore ISI from $77.00 to $89.00. They now have an “outperform” rating on the stock.
• 8/7/2025 – Mirum Pharmaceuticals had its “strong-buy” rating reaffirmed by analysts at Raymond James Financial, Inc..
• 8/7/2025 – Mirum Pharmaceuticals had its price target raised by analysts at Raymond James Financial, Inc. from $77.00 to $82.00. They now have a “strong-buy” rating on the stock.
• 8/7/2025 – Mirum Pharmaceuticals was given a new $81.00 price target on by analysts at JMP Securities. They now have a “market outperform” rating on the stock.
• 8/7/2025 – Mirum Pharmaceuticals had its price target raised by analysts at HC Wainwright from $73.00 to $80.00. They now have a “buy” rating on the stock.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, CFO Eric Bjerkholt sold 9,578 shares of Mirum Pharmaceuticals stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $76.01, for a total value of $728,023.78. Following the completion of the transaction, the chief financial officer owned 39,945 shares in the company, valued at $3,036,219.45. This trade represents a 19.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Laura Brege sold 17,000 shares of Mirum Pharmaceuticals stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $74.40, for a total transaction of $1,264,800.00. Following the completion of the transaction, the director owned 15,703 shares of the company’s stock, valued at $1,168,303.20. The trade was a 51.98% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 117,055 shares of company stock worth $7,286,235 over the last three months. Company insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.